Year All20242023202220212020201920182017201620152014 Feb 20, 2018 Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome Dec 12, 2017 Soleno Therapeutics Announces $15 Million Private Placement Dec 08, 2017 Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology Nov 22, 2017 Soleno Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference Nov 14, 2017 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results Oct 23, 2017 Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements Oct 12, 2017 Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome Oct 11, 2017 Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome Oct 05, 2017 Soleno Therapeutics Announces 1-for-5 Reverse Stock Split Sep 25, 2017 Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome
Feb 20, 2018 Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome
Dec 08, 2017 Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology
Nov 14, 2017 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results
Oct 12, 2017 Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome
Oct 11, 2017 Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome
Sep 25, 2017 Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome